Stock 3705 YUNGSHIN GLOBAL HOLDING CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials YungShin Global Holding Corporation

Equities

3705

TW0003705000

Pharmaceuticals

End-of-day quote Taiwan S.E.
Other stock markets
 18:00:00 2024-06-04 EDT 		5-day change 1st Jan Change
55.9 TWD +1.08% Intraday chart for YungShin Global Holding Corporation +4.68% +20.22%
05-10 YungShin Global Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-29 YungShin Global Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 10,481 11,414 11,907 11,440 12,253 12,386
Enterprise Value (EV) 1 12,599 13,698 13,773 12,915 12,061 11,816
P/E ratio 15 x 15.2 x 15.1 x 15.6 x 14.6 x 15 x
Yield 5.59% 5.13% 4.47% 3.96% 5% 4.95%
Capitalization / Revenue 1.39 x 1.39 x 1.47 x 1.47 x 1.68 x 1.76 x
EV / Revenue 1.68 x 1.67 x 1.7 x 1.65 x 1.65 x 1.68 x
EV / EBITDA 10.9 x 10.8 x 10.3 x 9.65 x 10.8 x 9.77 x
EV / FCF 39.8 x 182 x 28.7 x 34.9 x 14.1 x 13.1 x
FCF Yield 2.51% 0.55% 3.48% 2.87% 7.07% 7.62%
Price to Book 1.72 x 1.83 x 1.86 x 1.75 x 1.71 x 1.69 x
Nbr of stocks (in thousands) 266,365 266,365 266,365 266,365 266,365 266,365
Reference price 2 39.35 42.85 44.70 42.95 46.00 46.50
Announcement Date 19-03-29 20-03-31 21-03-31 22-03-31 23-03-31 24-03-29
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7,514 8,192 8,085 7,805 7,312 7,028
EBITDA 1 1,159 1,269 1,335 1,338 1,115 1,209
EBIT 1 802.2 891.9 960.7 957.6 757.3 929.6
Operating Margin 10.68% 10.89% 11.88% 12.27% 10.36% 13.23%
Earnings before Tax (EBT) 1 933.2 1,012 1,024 998.5 1,064 1,137
Net income 1 702 748.6 791.7 736.6 839 827.3
Net margin 9.34% 9.14% 9.79% 9.44% 11.48% 11.77%
EPS 2 2.630 2.810 2.970 2.760 3.150 3.106
Free Cash Flow 1 316.6 75.27 479.9 370.3 853.2 900.5
FCF margin 4.21% 0.92% 5.94% 4.74% 11.67% 12.81%
FCF Conversion (EBITDA) 27.31% 5.93% 35.94% 27.66% 76.48% 74.46%
FCF Conversion (Net income) 45.1% 10.05% 60.62% 50.27% 101.68% 108.84%
Dividend per Share 2 2.200 2.200 2.000 1.700 2.300 2.300
Announcement Date 19-03-29 20-03-31 21-03-31 22-03-31 23-03-31 24-03-29
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 2,118 2,284 1,866 1,474 - -
Net Cash position 1 - - - - 192 570
Leverage (Debt/EBITDA) 1.827 x 1.8 x 1.398 x 1.102 x - -
Free Cash Flow 1 317 75.3 480 370 853 900
ROE (net income / shareholders' equity) 11.2% 12% 12% 11.3% 11.8% 11.2%
ROA (Net income/ Total Assets) 4.4% 4.62% 4.81% 4.86% 3.97% 4.97%
Assets 1 15,951 16,199 16,464 15,151 21,151 16,635
Book Value Per Share 2 22.80 23.50 24.00 24.50 26.90 27.60
Cash Flow per Share 2 4.410 4.920 5.550 4.450 7.350 5.580
Capex 1 461 610 316 175 150 86.3
Capex / Sales 6.14% 7.44% 3.91% 2.24% 2.05% 1.23%
Announcement Date 19-03-29 20-03-31 21-03-31 22-03-31 23-03-31 24-03-29
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
YUNGSHIN GLOBAL HOLDING CORPORATION Stock YungShin Global Holding Corporation
+20.22% 455M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.69% 750B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 606B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.87% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.74% 326B
ABBVIE INC. Stock AbbVie Inc.
+6.76% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.08% 246B
ROCHE HOLDING AG Stock Roche Holding AG
-3.44% 213B
NOVARTIS AG Stock Novartis AG
+11.35% 213B
PFIZER, INC. Stock Pfizer, Inc.
+2.64% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 3705 Stock
  4. Financials YungShin Global Holding Corporation